The OHSU Knight Cancer Institute (Knight) is a matrix cancer center at the Oregon Health &Science University (OHSU) in Portland, Oregon. Founded in 1992 by Grover C. Bagby, Jr. M.D., the Knight has been broadly supported by the university administrative leaders, who have provided space and resources at steadily increasing levels. The Knight Cancer Institute has been supported by the NCI Cancer Center Support Grant since 1997. The OHSU Knight Cancer Institute has 151 members who belong to four scientific programs (Cancer Biology, Hematologic Malignancies, Solid Tumors, and Cancer Prevention and Control). Knight members utilize eight well-established shared resources to perform outstanding research, convert research findings into treatments and preventive agents, and design clinical trials to validate molecular targets. The new Director, Brian Druker, M.D. has sought to refocus the direction of the Knight onto the core values of changing cancer medicine. Institutional investments have added more than 200,000 sq ft in research and clinical space. Sixty-two new members have been added to the Knight, including significant changes in the senior leadership. A gift of $100 million from Phil and Penny Knight (to be given in installments over five to seven years) led to renaming the OHSU Cancer Institute to the OHSU Knight Cancer Institute. Our goal is to invest in people and programs that will advance our mission to make personalized cancer therapy and prevention a reality. As the recognized leader in personalized cancer therapies, our focus has been and will continue to be on investing to make personalized cancer therapy a reality. Investments in people and programs will help us achieve the following goals: 1.) Develop the methodology and capacity to rapidly and comprehensively interrogate individual patient tumors, 2.) Develop the capacity to organize the molecular data into interpretable, pathway focused information, 3.) Develop strategies to understand which pathway alterations are important, 4.) Develop a library of approved and investigational agents that are available to us for human use, 5.) Develop the capacity to rapidly test combinations of therapies targeting multiple genetic abnormalities in cancers, 6.) Develop novel clinical trial designs that will accommodate multi-agent therapies, 7.) Initiate innovative, multi-pathway phase I clinical trials to test our strategy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-16
Application #
8504951
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-06-22
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
16
Fiscal Year
2013
Total Cost
$1,061,540
Indirect Cost
$372,228
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Le, T Domi; Carney, Patricia A; Lee-Lin, Frances et al. (2014) Differences in knowledge, attitudes, beliefs, and perceived risks regarding colorectal cancer screening among Chinese, Korean, and Vietnamese sub-groups. J Community Health 39:248-65
Ruffell, Brian; Chang-Strachan, Debbie; Chan, Vivien et al. (2014) Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26:623-37
Martin, Jessica L; Yates, Phillip A; Soysa, Radika et al. (2014) Metabolic reprogramming during purine stress in the protozoan pathogen Leishmania donovani. PLoS Pathog 10:e1003938
Hitzemann, Robert; Bottomly, Daniel; Iancu, Ovidiu et al. (2014) The genetics of gene expression in complex mouse crosses as a tool to study the molecular underpinnings of behavior traits. Mamm Genome 25:12-22
Liu, Betty Y; O'Malley, Jean; Mori, Motomi et al. (2014) The association of type and number of chronic diseases with breast, cervical, and colorectal cancer screening. J Am Board Fam Med 27:669-81
Affara, Nesrine I; Ruffell, Brian; Medler, Terry R et al. (2014) B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25:809-21
Cope, Leslie M; Fackler, Mary Jo; Lopez-Bujanda, Zoila et al. (2014) Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS One 9:e105545
Caputo, Nicholas; Jackson, Melanie A; Castle, Jessica R et al. (2014) Biochemical stabilization of glucagon at alkaline pH. Diabetes Technol Ther 16:747-58
Yao, Huilan; Goldman, Devorah C; Nechiporuk, Tamilla et al. (2014) Corepressor Rcor1 is essential for murine erythropoiesis. Blood 123:3175-84
Davare, Monika A; Lal, Sangeet; Peckham, Jennifer L et al. (2014) Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells. Biochem Biophys Res Commun 450:555-60

Showing the most recent 10 out of 88 publications